$16.20
-0.01-0.06%
Last update: Nov 3, 2:27 PM
ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. (ALPMY) Stock Price, Quote, News & History
ALPMYOTCPK
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
You can purchase shares of ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. (OTCPK:ALPMY) through any online brokerage.
There are no as such competitors for ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc..
There is no analysis for ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. to provide a consensus price target.
The stock price for ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. (OTCPK: ALPMY) is $16.2 last updated November 3, 2026 at 2:27 PM EST.
There are no upcoming dividends for ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc..
ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. does not have any upcoming earnings scheduled.
There is no upcoming split for ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc..
ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc. is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for...
